Publications by authors named "K Ohba"
In 2021, Enfortumab Vedotin (EV) was approved for the treatment of locally advanced and metastatic urothelial carcinoma (UC) in Japan. Some patients require withdrawal or dose reduction due to cutaneous symptoms associated with EV treatment. Currently, the only reported associations of EV with cutaneous symptoms are pre-treatment performance status (PS) and body weight.
View Article and Find Full Text PDFCardiac myxoma with high standardized uptake value of FDG-PET-CT in the right ventricular outflow tract.
Gen Thorac Cardiovasc Surg Cases
December 2024
Background: Cardiac myxoma rarely occurs in the right ventricle, and as is a benign disease, it rarely shows high positivity on 18F fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT).
Case Presentation: We present herein the case of a 77-year-old woman who was found to have a heart murmur during a routine health checkup. Further examination revealed a 27-mm tumor in the right ventricular outflow tract (RVOT) and moderate aortic valve stenosis.
: This study aimed to investigate the relationship between lower urinary tract symptoms (LUTS) and tooth loss due to chronic periodontitis. : A total of 232 patients aged 40 years or older with LUTS were evaluated. The number of remaining teeth and the severity of LUTS were assessed using the overactive bladder symptom score, international prostate symptom score, and urodynamic tests.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates why some patients still have hypertension after undergoing adrenalectomy for primary aldosteronism and aims to identify factors influencing their prognosis.
- It analyzed data from 71 patients treated between 2008 and 2022, focusing on various factors like BMI, hypertension duration, and metabolic syndrome-related diseases.
- Key findings suggest that longer duration of hypertension, the presence of metabolic syndrome-related diseases, and higher doses of antihypertensive medications are predictors of persistent hypertension after surgery.
Article Synopsis
- The text discusses a study on the use of enfortumab vedotin in patients with metastatic urothelial carcinoma who are also on hemodialysis due to end-stage renal disease.
- Two case studies are presented: one involving an 85-year-old man and another a 73-year-old man, both of whom had undergone previous surgeries and treatments without success.
- The results showed varying responses to the treatment, with one patient achieving partial response and the other experiencing disease progression, while both encountered manageable side effects.